NOX-6-18 (GPR132-B-160) is a potent and selective antagonist of GPR132 with an IC50 of 17 nM. It regulates macrophage reprogramming within pancreatic islets, reduces weight gain, and improves glucose metabolism in mice on a high-fat diet.

NOX-6-18 (GPR132-B-160) is a potent and selective antagonist of GPR132 with an IC50 of 17 nM. It regulates macrophage reprogramming within pancreatic islets, reduces weight gain, and improves glucose metabolism in mice on a high-fat diet.

LDHA-IN-3, a selenobenzene derivative, is a potent noncompetitive inhibitor of Lactate Dehydrogenase A (LDHA), with an IC50 of 145.2 nM. It exhibits significant anti-tumor activity, effectively reducing LDHA activity and lactate production under both normoxic and hypoxic conditions. It also induces mitochondria-mediated apoptosis through the generation of reactive oxygen species.

NOX-6-18 (GPR132-B-160) is a potent and selective antagonist of GPR132 with an IC50 of 17 nM. It regulates macrophage reprogramming within pancreatic islets, reduces weight gain, and improves glucose metabolism in mice on a high-fat diet.

LDHA-IN-3, a selenobenzene derivative, is a potent noncompetitive inhibitor of Lactate Dehydrogenase A (LDHA), with an IC50 of 145.2 nM. It exhibits significant anti-tumor activity, effectively reducing LDHA activity and lactate production under both normoxic and hypoxic conditions. It also induces mitochondria-mediated apoptosis through the generation of reactive oxygen species.

LDHA-IN-3, a selenobenzene derivative, is a potent noncompetitive inhibitor of Lactate Dehydrogenase A (LDHA), with an IC50 of 145.2 nM. It exhibits significant anti-tumor activity, effectively reducing LDHA activity and lactate production under both normoxic and hypoxic conditions. It also induces mitochondria-mediated apoptosis through the generation of reactive oxygen species.

LDHA-IN-3, a selenobenzene derivative, is a potent noncompetitive inhibitor of Lactate Dehydrogenase A (LDHA), with an IC50 of 145.2 nM. It exhibits significant anti-tumor activity, effectively reducing LDHA activity and lactate production under both normoxic and hypoxic conditions. It also induces mitochondria-mediated apoptosis through the generation of reactive oxygen species.

Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively.

Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively.

TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo.